MACH-NC荟萃分析更新:107项随机试验与19805例头颈癌患者
MACH-NC协作组更新了头颈鳞癌化疗荟萃分析,纳入1965至2016年间107项随机试验共19805例无远处转移患者,采用固定效应模型汇总个体患者数据。主要问题分析101项试验18951例患者,中位随访6.5年,证实同期化疗显著改善总生存,5年绝对获益6.5%,而诱导或辅助化疗未增加总生存。
要点
- 同期化疗显著改善无远处转移头颈癌总生存,HR 0.83,5年绝对获益6.5%。
- 诱导化疗和辅助化疗均未显著增加总生存,HR分别为0.96和1.02。
- 同期化疗疗效随年龄增长而下降,趋势检验P=0.03。
核心结论
- MACH-NC更新证实,对无远处转移头颈癌,在局部区域治疗基础上加用同期化疗可显著改善总生存,且优于诱导或辅助化疗。
研究设计与样本
- 纳入1965至2016年间发表的随机试验,比较根治性局部区域治疗与局部区域治疗加化疗,或比较诱导化疗加放疗与放疗加同期(或交替)化疗。
- 主要问题分析101项试验共18951例患者,中位随访6.5年;两个问题合计新增16项试验2767例患者,更新11项试验。
- 收集个体患者数据,采用固定效应模型合并,主要终点为总生存。
主要发现
- 治疗效应与化疗时机存在显著交互作用(p < 0.0001),获益仅限于同期化疗(HR: 0.83, 95%CI [0.79; 0.86]),5年绝对获益6.5%,10年绝对获益3.6%。
- 加用诱导化疗未增加总生存(HR = 0.96 [0.90; 1.01]),加用辅助化疗亦未增加总生存(HR = 1.02 [0.92; 1.13])。
- 同期化疗疗效随年龄增长而下降(p_trend = 0.03);诱导化疗疗效随体能状态变差而下降(p_trend = 0.03)。
- 次要问题分析8项试验共1214例患者,证实同期化疗对总生存的优越性(HR = 0.84 [0.74; 0.95], p = 0.005)。
- 约90%患者为III期或IV期疾病。
关键数值与推荐
- 同期化疗对比单纯局部区域治疗:总生存HR 0.83(95%CI [0.79; 0.86]),5年绝对获益6.5%,10年绝对获益3.6%。
- 诱导化疗加局部区域治疗:总生存HR 0.96(95%CI [0.90; 1.01]),无显著获益。
- 辅助化疗:总生存HR 1.02(95%CI [0.92; 1.13]),无显著获益。
- 诱导化疗对比同期化疗(次要问题):总生存HR 0.84(95%CI [0.74; 0.95], p = 0.005),支持同期化疗。
临床怎么用
- 对无远处转移头颈鳞癌,根治性局部区域治疗应联合同期化疗以改善总生存。
- 不推荐常规加用诱导化疗或辅助化疗以期改善总生存。
- 选择同期化疗时需考虑年龄对疗效的影响,老年患者获益可能减小。
局限性
- 原文未报告各试验间具体化疗方案、放疗技术及毒性数据的汇总分析。
- 约90%患者为III–IV期,结论对早期患者的外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The Meta-Analysis of Chemotherapy in squamous cell Head and Neck Cancer (MACH-NC) demonstrated that concomitant chemotherapy (CT) improved overall survival (OS) in patients without distant metastasis. We report the updated results. MATERIALS AND METHODS: Published or unpublished randomized trials including patients with non-metastatic carcinoma randomized between 1965 and 2016 and comparing curative loco-regional treatment (LRT) to LRT + CT or adding another timing of CT to LRT + CT (main question), or comparing induction CT + radiotherapy to radiotherapy + concomitant (or alternating) CT (secondary question) were eligible. Individual patient data were collected and combined using a fixed-effect model. OS was the main endpoint. RESULTS: For the main question, 101 trials (18951 patients, median follow-up of 6.5 years) were analyzed. For both questions, there were 16 new (2767 patients) and 11 updated trials. Around 90% of the patients had stage III or IV disease. Interaction between treatment effect on OS and the timing of CT was significant (p < 0.0001), the benefit being limited to concomitant CT (HR: 0.83, 95%CI [0.79; 0.86]; 5(10)-year absolute benefit of 6.5% (3.6%)). Efficacy decreased as patients age increased (p_trend = 0.03). OS was not increased by the addition of induction (HR = 0.96 [0.90; 1.01]) or adjuvant CT (1.02 [0.92; 1.13]). Efficacy of induction CT decreased with poorer performance status (p_trend = 0.03). For the secondary question, eight trials (1214 patients) confirmed the superiority of concomitant CT on OS (HR = 0.84 [0.74; 0.95], p = 0.005). CONCLUSION: The update of MACH-NC confirms the benefit and superiority of the addition of concomitant CT for non-metastatic head and neck cancer.
引用
- Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021. PMID: 33515668. doi:10.1016/j.radonc.2021.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。